Merck KGaA (MRK) Given a €98.00 Price Target at Morgan Stanley

Morgan Stanley set a €98.00 ($116.67) price objective on Merck KGaA (FRA:MRK) in a report released on Friday, December 1st. The brokerage currently has a neutral rating on the healthcare company’s stock.

Other equities research analysts have also issued research reports about the stock. S&P Global set a €110.00 ($130.95) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Thursday, August 3rd. equinet set a €112.00 ($133.33) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Thursday, August 31st. BNP Paribas set a €116.00 ($138.10) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, September 6th. Warburg Research set a €115.00 ($136.90) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, September 6th. Finally, Bank of America set a €110.00 ($130.95) target price on shares of Merck KGaA and gave the stock a buy rating in a report on Wednesday, September 6th. Twelve research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of €107.81 ($128.34).

Merck KGaA (MRK) opened at €91.07 ($108.42) on Friday. Merck KGaA has a 52 week low of €87.33 ($103.96) and a 52 week high of €115.00 ($136.90).

COPYRIGHT VIOLATION WARNING: “Merck KGaA (MRK) Given a €98.00 Price Target at Morgan Stanley” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/12/13/morgan-stanley-analysts-give-merck-kgaa-mrk-a-98-00-price-target.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply